publication date: Jun. 15, 2018
The Trump administration “American Patients First” plan to reduce drug prices—Are American cancer patients first?
Chairman, Department of Leukemia, MD Anderson Cancer Center
Baker Institute Special Fellow for Health Policies, Rice University Baker Institute
Mary Alma Welch
Manager, Advanced Practice Providers, Department of Leukemia, MD Anderson Cancer Center
In May 2018, President Trump announced his plan to lower drug prices. “We will have tougher negotiation, more competition, and much lower prices at the pharmacy counter. And it will start to take effect very soon,” he promised. The plan is outlined in a 40-page document by the U.S. Department of Health and Human Services titled “American Patients First—The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Cost.” (1)
The Food and Drug Administration followed with parallel plans to complement the administration’s strategies (2, 3). The HHS Secretary Alex Azar, a previous CEO of pharmaceutical company Eli Lilly, identified four major challenges: “high list prices for drugs; senior and government programs overpaying for drugs due to lack of the latest negotiation tools; high … Continue reading The Trump administration “American Patients First” plan to reduce drug prices—Are American cancer patients first?
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.